A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

Interleukin 17 contributes to the chronicity of inflammatory diseases such as rheumatoid arthritis

(2013) Giulia Benedetti et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis

(2013) Bruce W. Kirkham et al.   IMMUNOLOGY

Combination of IL-17 and TNFα induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells

(2012) Arnaud Hot et al.   ANNALS OF THE RHEUMATIC DISEASES

Targeting IL-17 and TH17 cells in chronic inflammation

(2012) Pierre Miossec et al.   NATURE REVIEWS DRUG DISCOVERY

Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF

(2010) Laura E. DeForge et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Interleukin-17 and Type 17 Helper T Cells

(2009) Pierre Miossec et al.   NEW ENGLAND JOURNAL OF MEDICINE